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Abstract
Background: The exacting nutritional requirements and complicated life cycles of parasites mean that they are not always
amenable to high-throughput drug screening using automated procedures. Therefore, we have engineered the yeast
Saccharomyces cerevisiae to act as a surrogate for expressing anti-parasitic targets from a range of biomedically important
pathogens, to facilitate the rapid identification of new therapeutic agents.
Methodology/Principal Findings: Using pyrimethamine/dihydrofolate reductase (DHFR) as a model parasite drug/drug
target system, we explore the potential of engineered yeast strains (expressing DHFR enzymes from Plasmodium falciparum,
P. vivax, Homo sapiens, Schistosoma mansoni, Leishmania major, Trypanosoma brucei and T. cruzi) to exhibit appropriate
differential sensitivity to pyrimethamine. Here, we demonstrate that yeast strains (lacking the major drug efflux pump,
Pdr5p) expressing yeast (ScDFR1), human (HsDHFR), Schistosoma (SmDHFR), and Trypanosoma (TbDHFR and TcDHFR) DHFRs are
insensitive to pyrimethamine treatment, whereas yeast strains producing Plasmodium (PfDHFR and PvDHFR) DHFRs are
hypersensitive. Reassuringly, yeast strains expressing field-verified, drug-resistant mutants of P. falciparum DHFR
(Pfdhfr51I,59R,108N) are completely insensitive to pyrimethamine, further validating our approach to drug screening. We
further show the versatility of the approach by replacing yeast essential genes with other potential drug targets, namely
phosphoglycerate kinases (PGKs) and N-myristoyl transferases (NMTs).
Conclusions/Significance: We have generated a number of yeast strains that can be successfully harnessed for the rapid
and selective identification of urgently needed anti-parasitic agents.
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Introduction
Parasitic diseases such as malaria, schistosomiasis, leishmaniasis,
sleeping sickness, and Chagas disease affect millions of people every
year, leading to severe morbidity and death. For example malaria,
caused by parasites of the genus Plasmodium, kills 1–3 million people
every year (http://www.who.int/mediacentre/factsheets/fs094/
en/index.html). The disease is primarily treated by chloroquine,
artemisinin, and antifolates (e.g. pyrimethamine). However, Plas-
modium spp. have become resistant to all of these drugs [1].
Schistosomiasis, caused by the blood fluke Schistosoma, is the second
most important parasitic disease worldwide, affecting ca. 207 mil-
lion people (http://www.who.int/mediacentre/factsheets/fs115/en/
index.html) [2], and causing the death of greater than 300,000
individuals per annum [3]. Schistosomiasis is commonly treated
through administration of praziquantel, but the sole use of this
drug against all human infective schistosome species raises the
concern that drug-resistant parasites may develop [4]. Sleeping
sickness (or African trypanosomiasis), caused by Trypanosoma
brucei, infects about 300,000 people each year leading to about
40,000 deaths [5,6]. Chagas disease, caused by T.cruzi, is endemic
to Latin America, where ca. 17 million people are infected,
leading to about 21,000 deaths reported each year [7]. Very few
drugs are available for the treatment of patients infected with
Trypanosoma spp. and none is satisfactory due to low efficacy, high
cost, or unacceptable side effects [8,9,10]. Leishmaniasis, caused
by Leishmania spp. is endemic in 88 countries affecting 12 million
people (http://www.who.int/leishmaniasis/en/). It is traditional-
ly treated with antimony compounds, but resistance to this class
of drugs is increasing and very few novel drugs are under
development. All of this demonstrates that the design or discovery
of novel antiparasitic drugs is a global imperative.
For the past 30 years, the yeast Saccharomyces cerevisiae has been
used successfully as a vehicle for the expression of heterologous
proteins with the aim of understanding their function, producing
high levels of recombinant protein, or studying the effect of drugs
on defined targets (for review see [11]). By performing genome-
wide drug sensitivity screens (chemogenomic profiling)
[12,13,14,15,16,17] of yeast mutants with the antimalarials
quinine [18], St. John’s Wort [19] and artemisinin [20],
researchers were able to identify their primary targets as well as
identify potential side effects. Furthermore, several groups have
been able to complement yeast loss-of function mutations by
expressing coding sequences from parasites such as Plasmodium
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[21,22], Schistosoma [23,24,25], Leishmania [26] or Trypanosoma
[6,27,28,29,30,31].
Yeast cells expressing parasite proteins potentially provide a
well-characterised platform for functional studies of heterologous
proteins as well as for screens attempting to identify novel drugs
including antiparasitics [32,33,34,35]. For instance, Geary and co-
workers expressed potential drug targets for Haemonchus contortus
(wireworm, an important parasite of ruminants) in Escherichia coli
[36,37] and later in Saccharomyces cerevisiae [38], and pioneered the
development of high-throughput drug screens for antiparasitics in
yeast [38].
A well-characterised anti-parasitic drug target is dihydrofolate
reductase (DHFR). DHFR is the enzyme responsible for
converting dihydrofolate into tetrahydrofolate, an intermediate
in the synthesis of purines, thymidylic acid, and certain amino
acids (e.g. methionine). DHFR is present in organisms ranging
from bacteria to humans and is the target of pyrimethamine
treatment of malaria and human tumours, since rapidly growing
cells require folate to produce thymine [39]. Sibley and co-workers
[22,40,41] have done extensive work on the complementation of
yeast dfr1 mutations by overexpression of human and Plasmodium
DHFRs and demonstrated the suitability of the strains for drug
screens in plate assays.
Phosphoglycerate kinase (PGK) is a central enzyme in glycolysis
and gluconeogesis; it catalyzes the transfer of high-energy
phosphoryl groups from the acyl phosphate of 1,3-bisphosphogly-
cerate to ADP to produce ATP. PGKs are essential for the blood
stages of parasites but the human enzyme is not expressed in
erythrocytes; therefore, the enzyme has been proposed as a drug
target [42,43].
N-myristoyltransferase (NMT) is an enzyme responsible for the
co- and post-translational modification of proteins by transferring
myristate groups to N-terminal glycine residues, allowing their
targeting to various membranes [5,44]. NMTs are essential
enzymes conserved from kinetoplastid parasites to humans and
have been successfully demonstrated as drug targets [5].
In spite of the pressing need for new treatments targeting
neglected diseases, pharmaceutical companies have had little
interest in the research and development of new medicines
towards diseases affecting overwhelmingly or exclusively developing
countries [45,46]. Thankfully, with the investment of funds from
organizations such as the Bill and Melinda Gates Foundation,
Medicines for Malaria Venture (MMV), the Drugs for Neglected
Diseases initiative (DNDi), and the Institute for One World Health
(IOWH) this scenario is changing [47,48]. Now, pharmaceutical
giants such as Novartis [49], GSK [50], Pfizer (just to name a few)
investing great efforts in the development of novel antimalarials
(www.mmv.org/research-development/science-portfolio). Howev-
er, due to the diversity of parasite species and their complex life
cycles, the development of inexpensive and rapid drug screening
methods is a constant challenge. Various groups have developed
efficient high-throughput drug screening methods based on intact
parasites [51,52,53,54]. However, these are specific to one or a few
parasite species and do not always provide information concerning
the target of the hit compound. Conversely, the standard alternative
of using pure proteins as targets can be unsatisfactory because the
assay neglects all other biological interactions of the candidate
compounds [35]. Tomeet this challenge, we have developed a series
of yeast strains that can be used to screen for drugs against multiple
drug targets from multiple parasites with a single experimental
set-up.
Methods
Construction of plasmid maps and phylogenetic trees
We constructed plasmid maps and Genbank files of the
constructs expressing heterologous protein using the program
CLC Genomics Workbench. We translated the coding regions of
each of the proteins and performed protein alignments of them
against Saccharomyces cerevisiae Dfr1p, Nmt1p and Pgk1p. We
constructed the similarity tree using the standard settings from
CLC Genomics Workbench (neighbor-joining, bootstrap analysis,
100 replicates).
Strain and plasmid constructs
The DHFR/PGK/NMT-coding regions of Schistosoma mansoni
(Sm), Saccharomyces cerevisiae (Sc), Leishmania major (Lm), Trypanosoma cruzi
(Tc) and T.brucei (Tb) were PCR amplified from genomic DNA
templates and cloned into pCM188 [55]. The following plasmids
were constructed: pCMSmDHFR (pCM188 with the complete open
reading frame of Schistosoma mansoni DHFR under the control
of the tetracycline regulatable promoter TetO2), pCMScDHFR,
pCMLmDHFR, pCMTcDHFR, pCMTbDHFR, pCMSmPGK,
pCMLmPGKB, pCMTcPGK, pCMTbPGK, pCMSmNMT, pCMLmNMT,
pCMTcNMT, pCMTbNMT (Table S1).
Human (Hs) PGK and NMT2 were PCR amplified from a
human cerebellum cDNA library and cloned into pCM188 to
produce pCMHsPGK and pCMHsNMT2 (Table S1).
The DHFR coding sequences from human, Plasmodium
falciparum (Pf), and P.vivax (Pv), as well as PGK and NMT from
P.vivax, were synthesised by GENEART with a codon usage
suitable for expression in yeast. These synthetic constructs were
sub-cloned into pCM188 to generate pCMHsDHFR, pCMPfDHFR,
pCMPvDHFR, pCMPvPGK and pCMPvNMT (Table S1).
The DHFR mutations N51I, C59R and S108N confer
resistance to antifolates in wild Plasmodium falciparum populations;
we designate such resistant alleles by the preceding superscript Pfr
and give the amino-acid changes in parentheses in a succeeding
superscript. Two rounds of site-directed mutagenesis were
performed to introduce these mutations into pCMPfDHFR to
generate pCMPfRdhfr(51I,59R,108N) (Table S1). All constructs were
verified by sequencing (Figures S1, S2, S3, S4, S5, S6, S7, S8 and
Author Summary
Parasites kill millions of people every year and leave
countless others with chronic debilitating disease. These
diseases, which include malaria and sleeping sickness,
mainly affect people in developing countries. For this
reason, few drugs have been developed to treat them. To
make matters worse, many parasites are developing
resistance to the drugs that are available. Thus, there is
an urgent need to develop new drugs, but this is
hampered by the fact that most parasites are difficult or
impossible to grow in the laboratory. To address this, we
have engineered baker’s yeast to be dependent on the
function of enzymes from either parasites or humans. In all,
our engineered yeast constructs encompass six parasites
(causing malaria, schistosomiasis, leishmaniasis, sleeping
sickness, and Chagas disease) and three different enzymes
that are known or potential drug targets. Further, we have
increased yeast’s sensitivity to drugs by deleting the gene
for its major drug efflux pump. Because yeast is robust and
easy to grow in the laboratory, we can use a robot to
screen for drugs that will kill yeast dependent on a parasite
enzyme, but not touch yeast dependent on the equivalent
human enzyme.
Expression of Parasite Drug Targets in Yeast
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Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14,
S15, S16, S17, S18, S19, S20, S21).
Deletions of the yeast PDR5 coding sequence (specifying the
major drug efflux pump) from dfr1, pgk1 and nmt1 heterozygous
mutant strains were performed as previously described [56]. pCM-
DHFR constructs were transformed into dfr1D::KanMX/DFR1
pdr5D::HisMX/PDR5 strains (BY4743 background [57]). pCM-
PGK constructs were transformed into pgk1D::KanMX/PGK1
pdr5D::HisMX/PDR5 strains (BY4743 background). pCM-NMT
constructs were transformed into nmt1D::KanMX/NMT1
pdr5D::HisMX/PDR5 strains (BY4743 background). Heterozygous
diploid strains were then sporulated and dissected using a
micromanipulator (Singer MSM). Derived haploids with the
genotype dfr1D::KanMx MET15 lys2D0 MATa, pgk1D::KanMx
MET15 lys2D0 MATa or nmt1D::KanMx met15 LYS2 MATa were
selected for drug screens (Table S2).
Growth conditions
Standard growth conditions and either YPD (2% peptone, 1%
yeast extract, 2% glucose) or YNB-glucose (0.68% yeast nitrogen
base, 2% ammonium sulphate, 2% glucose) with the relevant
supplements were used for all assays.
Liquid growth assays and maximum growth rate
calculations
Cultures of wild type (BY4741) and transformant yeast strains
were inoculated into 200 ml of YPD in the wells of 96-well
microtiter plates and grown for 40 hours at 30uC. Growth was
monitored with the BMG Optima multiplate reader. Each sample
was present in quadruplicates, distributed randomly throughout
the plate and OD595 measurements were made ever 10 minutes. A
384-well plate (with 70 ml of YPD + doxycycline) was prepared in
a similar manner.
The OD readings from the plate reader were log-transformed
and 7 consecutive readings were used to calculate exponential
growth rate of the culture in each well. These exponential growth
rates were then normalized by dividing by the average exponential
growth rate of the wild type culture grown on the same plate.
Normalized growth rates were averaged across the 4 or 5
replicates and standard deviations calculated.
Plate assays for drug sensitivity
Serial dilutions (5x) of stationary phase cultures were prepared
in 96-well plates and replicated onto agar plates manually or in
quadruplicate onto agar plates using a robot (Singer RoToR).
Cells were allowed to grow for 2 days at 30uC.
Quantification of growth on agar plates
Strains were spotted in four replicates (Figure S10). Each pair of
rows on the image corresponds to a strain, spotted in increasing
dilutions (1:1, 1:5, 1:25 …) in blocks of four. The images of the
plates were produced in Gel Doc 2000 (BioRad) and saved as .jpg
files. Matlab was used to convert the images to three-dimensional
matrices, the first and second dimensions were the vertical and
horizontal dimensions of the image and third dimension was the
colour channel in RBG 24-bit format. As the images were saved in
grey scale, choice of channel did not make a major impact on
quantification of colonies; third channel (Green) was used.
The average intensities of pixels on each column and row in the
image were calculated, intersection points of rows and columns
with highest average intensity among their neighbours (in a
window of 565) were set as the spot or colony centres. Once the
colony centres were set, a 16 pixels616 pixels diamond shape
colony frame was set around each colony centre, and average
intensity was calculated for each colony frame. Then the pixels
with 50% larger intensity than the average of the colony frame
were counted and recorded as the colony size.
Results
Defining the drug targets
We have defined our candidate drug targets based on the
following criteria: (i) the target should be an enzyme that is
essential in yeast (this permits verification of the functional
expression of the target); (ii) the target should be essential, or
predicted to be essential, in most parasites; (iii) it may be present in
human (a ‘humanized’ yeast strain will be used as a control in the
screens); (iv) there should be a low similarity between human and
parasite proteins; (v) the target should be one suggested by the
TDR targets database (http://tdrtargets.org/). Combining these
criteria, we selected 4 drug targets for expression in yeast:
dihydrofolate reductase (DHFR, EC:1.5.1.3), phosphoglycerate
kinase (PGK, EC:2.7.2.3), N-myristoyl transferase (NMT,
EC:2.3.1.97), and farnesyl pyrophosphate synthetase (FPS,
EC:2.5.1.1, EC:2.5.1.10). As explained in the Introduction, all of
these enzymes have previously been proposed as useful targets for
antiparasitic drugs, and many have been used in drug screens
[5,22,41,42,43,44,58].
Complementation
We have constructed a series of four plasmids containing the
coding sequences (cds) for human DHFR, PGK, NMT, and FPS
and transformed these into diploid yeast strains that are
heterozygous deletion mutants for the gene encoding the
corresponding essential enzyme, namely: DFR1 (ScDHFR), PGK1
(ScPGK), NMT1 (ScNMT) or ERG20 (ScFPS). The transformed
diploids were then sporulated. Two of the four haploid spores in
the tetrad will carry the deletion for the essential yeast gene and
will only grow if that mutation is complemented by the
orthologous human cds. We observed that the overexpression of
the cds for human DHFR (a synthetic gene codon-optimised for
expression in yeast was used), PGK or NMT2 could complement
the essential function of the yeast deletions (Figure 1), whereas
human FPS could not complement the deletion of the yeast FPS
(data not shown). We then constructed plasmids expressing codon-
optimized cds for Plasmodium vivax DHFR, NMT and PGK, P.
falciparum DHFR and drug resistant P. falciparum dhfr, and verified
that these heterologous sequences could also complement the yeast
deletions. We constructed strains expressing cds for Schistosoma
mansoni, Leishmania major, Trypanosoma cruzi and T. brucei DHFRs
and NMTs, and found that each of them could complement yeast
deletions, albeit with varying efficiencies (Figure 1). The same was
true for each of the Schistosoma mansoni, Trypanosoma cruzi, and T.
brucei PGKs tested. We tested whether cds for the different
Leishmania major PGKs – the cytosolic PGKB, the glycosomal
PGKC, and the putative PGK LmjF30.3380 - could complement
a yeast pgk1 deletion mutation. We found that only PGKB could
complement the yeast deletion and resulted in a slow-growth
phenotype (approximately 64% of the maximum growth rate of a
wild-type strain) even with full expression of the heterologous
protein (Figure 1).
Plasmid maps for all of these plasmids are shown in Figures S1,
S2, S3, S4, S5, S6, S7, S8 and the full sequences of the plasmids
can also be found in the Supplementary Material (Text S1, S2, S3,
S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17,
S18, S19, S20, S21).
Expression of Parasite Drug Targets in Yeast
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Modulated expression
We cloned cds for all of the heterologous proteins into pCM188
plasmids, under the control of a TetO2 promoter, to allow the
modulated expression of each drug target in yeast. TetO2 is a
powerful constitutive promoter but can be repressed by the
addition of a tetracycline analogue (doxycycline) to the growth
medium. Thus, normal growth conditions result in the full
expression on the cloned cds;, however, by adding doxycycline,
we can reduce the expression of the parasite or human cds to levels
that should be inversely proportional to the concentration of
doxycycline added . We measured the growth rate of the parasite
mimetic or human mimetic yeast strains in the presence of 2, 5, 10
or 20 mg/L doxycycline and found that the reduction in growth
rate of yeast expressing human or parasite cds for either DHFR or
NMT were relatively insensitive to the addition of doxycline (#
25%) growth-rate inhibition (Figure S9). In contrast, addition of
doxycline to strains express cds for PGK displayed up to 75%
growth-rate upon doxycycline treatment (Figure S9). While these
results indicate that only small amounts of the heterologous
enzymes are often sufficient to achieve full complementation of the
yeast deletion mutation, we demonstrate below that reduction in
enzyme concentration achieved by inhibiting promoter activity
with doxycycline is sufficient to enhance the sensitivity of yeast
growth to the action of drugs that inhibit the activity of target
enzymes to a useful extent.
Figure 1. Complementation of yeast dfr1, nmt1 and pgk1 deletion mutants with human and parasite orthologs. A) Maximum growth
rates of yeast strains expressing cds for heterologous dihydrofolate reductases (DHFRs), N-myristoyl transferases (NMTs) or phosphoglycerate kinases
(PGKs) from human (Hs), Leishmania major (Lm), Plasmodium falciparum (Pf and PfR), P.vivax (Pv), Schistosoma mansoni (Sm), Trypanosoma brucei (Tb)
or T. cruzi (Tc). B) Phylogenetic tree and maximum growth rate (% of wild-type growth) of the heterologous NMTs, DHFrs and PGKs. All strains are
pdr5D mutants.
doi:10.1371/journal.pntd.0001320.g001
Expression of Parasite Drug Targets in Yeast
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Plate assays
PGKs and NMTs are fairly novel drug targets and therefore we
had no access to specific inhibitors for the different species tested.
However, Plasmodium DHFRs are classic drug targets, which can
be specifically inhibited by the antimalarial drug pyrimethamine.
Therefore, we performed drug sensitivity assays (on agar plates) of
the different yeast transformants expressing parasite mimetic or
human DHFRs in the presence of various concentrations of
pyrimethamine. We found that yeast strains expressing Plasmodium
vivax DHFR (yPvDHFR) showed sensitivity to concentrations of
pyrimethamine ranging from 10 to 500 mM (Figure 2, upper
panels). Yeast strains expressing Plasmodium falciparum DHFR
(yPfDHFR) showed sensitivity to concentrations of pyrimethamine
ranging from 100 to 500 mM (Figure 2, upper panels). No other
strain showed sensitivity to the pyrimethamine concentrations
tested. Importantly, by modulating the expression of the
heterologous cds by adding 5 mg/L doxycycline to the growth
media, it was possible to increase the sensitivity of the strains to
pyrimethamine by approximately 50-fold (Figure 2, lower panels).
Effect of a pdr5 deletion on pyrimethamine sensitivity
With the aim of further increasing the sensitivity of our assays,
we deleted the PDR5 gene, which encodes the major yeast
multidrug export pump, from all of our strains and tested the effect
of such a deletion on the pyrimethamine sensitivity of strains
expressing heterologous DHFRs. We spotted (using a Singer
RoTor robot) serial dilutions of PDR5 and pdr5D strains onto
rectangular agar plates containing a series of concentrations of
pyrimethamine with or without doxycycline (5 mg/L). Following
quantification of the data (Figure S10), we observed that removal
of the multidrug export pump by the pdr5D deletion significantly
increased the strains’ sensitivity to pyrimethamine, such that (in
the presence of doxycycline) the sensitivity of the Trypanosoma brucei
DHFR could be observed (Figure 3).
Discussion
Yeast cells are suitable hosts for the expression of heterologous
proteins from various species, including enzymes essential to the
different life-cycle stages of parasites. Some of these parasite life
stages cannot be propagated under laboratory conditions, and thus
yeast provides a practical and flexible platform for in vivo drug
screens. Here, we have reported the construction of a series of
yeast strains that are identical apart from the cds for different
heterologous drug targets (DHFR, PGK or NMT) which they
express. For all of these targets, we also constructed yeast strains
expressing the cds for the equivalent human enzyme, thus
permitting the design of screens for agents that discriminate
between the parasite and human targets.
Sibley and co-workers [22,40,41] have done extensive work on
the complementation of yeast dfr1 mutations by overexpression of
human and Plasmodium DHFRs and demonstrated the suitability
of yeast strains for drug screens in plate assays. Now, we have
demonstrated that the DHFR cds from Schistosoma mansoni,
Leishmania major, Trypanosoma cruzi and T. brucei can also
successfully complement a dfr1 null mutant of yeast. Furthermore,
we have found that yeast cells expressing T. brucei DHFR are
partially sensitive to pyrimethamine (Figure 2) and that strains
expressing T. cruzi or S. mansoni DHFRs are sensitive to the
chemotherapeutic agent methotrexate (data not shown). In
addition, we have also successfully complemented yeast deletion
mutants with cds for two new potential drug targets from
parasites: N-myristoyl transferase (NMT) and phosphoglycerate
kinase (PGK). To the best of our knowledge, this is the first
evidence for the functional expression of these parasite enzymes
in yeast. While all of the data presented in this paper relate to
Figure 2. Pyrimethamine sensitivity of yeast strains expressing heterologous dihydrofolate reductases (DHFRs). Serial dilutions (5x) of
yeast cultures expressing cds for human (Hs), Plasmodium falciparum (Pf), drug resistant P. falciparum (PfR), P.vivax (Pv), Schistosoma mansoni (Sm),
Trypanosoma brucei (Tb), T. cruzi (Tc) or Saccharomyces cerevisiae (Sc) DHFRs spotted onto agar plates containing pyrimethamine at the stated doses
with or without doxycycline (5 mg/L).
doi:10.1371/journal.pntd.0001320.g002
Expression of Parasite Drug Targets in Yeast
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screens against yeast cells spotted onto agar plates, we have
confirmed all the results for DHFR using yeast strains grown in
liquid cultures in 384-well microtiter trays. Indeed, we intend to
use such liquid cultures in HTP screens based on the series of
yeast strains reported here.
Yeast cells may be refractory to chemotherapeutic drugs due
to their thick cell walls and the high levels of expression of
multiple drug efflux pumps. Thus the genetic manipulation of
yeast strains for use in screens in order to increase their drug
sensitivity is highly desirable. We have improved the drug
sensitivity of our yeast constructs in two ways. First, all cds
encoding heterologous enzymes that represent drug targets were
placed under control of the TetO2 promoter, so that their
expression could be down-regulated by addition of the
tetracycline analogue, doxycycline. We demonstrated that
additions of doxycycline to the growth medium enhanced the
pyrimethamine sensitivity of parasite DHFR enzymes expressed
in yeast (Figure 2). Second, we demonstrated (again using DHFR
and pyrimethamine) that the deletion of the gene PDR5, which
encodes the major yeast ABC transporter, can increase the
sensitivity of drug screens (Figure 3). Moreover the use of pdr5D
mutants in conjunction with pyrimethamine has a synergistic
effect on drug sensitivity (Figure 3). The ease of genetically
manipulation in yeast should allow further improvements in drug
sensitivity in the future; for instance, by modifying the sequence
or expression of genes (such CWP1, CWP2, or PSA1) that
encoding cell wall proteins [59].
We believe that many more enzyme targets and parasite species
can be studied using a similar approach and are currently employing
some of our strains in high-throughput drug screens using a Robot
Scientist [60,61,62] in search of novel antiparasitic agents.
Supporting Information
Figure S1 Map of pCM188. Plasmid backbone used for
cloning of the cds for heterologous DHFRs, NMTs and PGKs
under the control of the tetracycline-regulatable promotor: TetO2.
(TIF)
Figure S2 Maps of the Plasmodium falciparum comple-
mentation plasmids. Plasmids for expression of cds for
heterologous wild-type Plasmodium falciparum DHFR (PfDHFR)
and the drug-resistant Plasmodium falciparum DHFR (PfRdhfr)
under the control of the TetO2 promoter.
(TIF)
Figure S3 Maps of the Plasmodium vivax complemen-
tation plasmids. Plasmids for expression of cds for heterologous
Plasmodium vivax DHFR, NMT and PGK under the control of the
TetO2 promoter.
(TIF)
Figure 3. Effect of the drug efflux pump Pdr5p on sensitivity to pyrimethamine. Graphs showing the quantification of growth on agar
plates (containing the indicated concentrations of pyrimethamine +/- 5 mg/L of doxycycline) of yeast strains expressing cds for heterologous DHFRs.
Solid lines: PDR5 strains: dashed lines: pdr5D mutants.
doi:10.1371/journal.pntd.0001320.g003
Expression of Parasite Drug Targets in Yeast
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Figure S4 Maps of the Schistosoma mansoni comple-
mentation plasmids. Plasmids for expression of cds for
heterologous Schistosoma mansoni DHFR, NMT and PGK under
the control of the TetO2 promoter.
(TIF)
Figure S5 Maps of the Trypanosoma brucei comple-
mentation plasmids. Plasmids for expression of cds for
heterologous Trypanosoma brucei DHFR, NMT and PGK under
the control of the TetO2 promoter.
(TIF)
Figure S6 Maps of the Trypanosoma cruzi complemen-
tation plasmids. Plasmids for expression of cds for heterologous
Trypanosoma cruzi DHFR, NMT and PGK under the control of the
TetO2 promoter.
(TIF)
Figure S7 Maps of the human complementation plas-
mids. Plasmids for expression of cds for heterologous Homo sapiens
DHFR, NMT2 and PGK under the control of the TetO2 promoter.
(TIF)
Figure S8 Maps of the Leishmania major complemen-
tation plasmids. Plasmids for expression of cds for heterologous
Leishmania major DHFR, NMT and PGKB under the control of the
TetO2 promoter.
(TIF)
Figure S9 Effect of doxycycline on the maximum growth
rate of yeast strains expressing heterologous drug
targets. Maximum growth rates (relative to that of the wild
type) of yeast strains expressing cds for human or parasite DHFRs,
NMTs or PGKs under the control of the TetO2 promoter.
(TIF)
Figure S10 Quantification of the effect of pdr5D muta-
tions on pyrimethamine sensitivity. A) Example of plate
where serial dilutions of yeast cultures expressing cds for
heterologous DHFRs were spotted in quadruplicate onto agar
plates containing pyrimethamine and doxycycline. Wild-type
PDR5 strains were spotted on the left half of the plate and pdr5D
deletion mutants on the right half of the plate. B) The intercepts of
the brightest row and column of the spots were marked as`colony
centers`. C) The area enclosed by a diamond-shaped frame around
the colony center was set as the`colony window`. D) Number of
pixels brighter than the threshold within the colony window was
set as the`colony size`, which corresponds to spot’s total area.
(TIF)
Table S1 Plasmids used in this study. Details and source of
the complementation plasmids used in this work.
(DOC)
Table S2 Strains used in this study. Details and source of
strains used in this work.
(DOC)
Text S1 pCM188. Sequence and features of the plasmid
backbone used for cloning of the heterologous DHFRs, NMTs
and PGKs under the control of the tetracycline-regulatable
promoter: TetO2.
(GBK)
Text S2 pCMPfDHFR. Sequence and features of the Plasmo-
dium falciparum DHFR complementation plasmid.
(GBK)
Text S3 pCMPfRdhfr. Sequence and features of the drug-
resistant Plasmodium falciparum DHFR complementation plasmid.
(GBK)
Text S4 pCMPvDHFR. Sequence and features of the Plasmo-
dium vivax DHFR complementation plasmid.
(GBK)
Text S5 pCMSmDHFR. Sequence and features of the
Schistosoma mansoni DHFR complementation plasmid.
(GBK)
Text S6 pCMTbDHFR. Sequence and features of the
Trypanosoma brucei DHFR complementation plasmid.
(GBK)
Text S7 pCMTcDHFR. Sequence and features of the
Trypanosoma cruzi DHFR complementation plasmid.
(GBK)
Text S8 pCMHsDHFR. Sequence and features of the human
DHFR complementation plasmid.
(GBK)
Text S9 pCMLmDHFR. Sequence and features of the
Leishmania major DHFR complementation plasmid.
(GBK)
Text S10 pCMPvNMT. Sequence and features of the
Plasmodium vivax NMT complementation plasmid.
(GBK)
Text S11 pCMSmNMT. Sequence and features of the
Schistosoma mansoni NMT complementation plasmid.
(GBK)
Text S12 pCMTbNMT. Sequence and features of the
Trypanosoma brucei NMT complementation plasmid.
(GBK)
Text S13 pCMTcNMT. Sequence and features of the
Trypanosoma cruzi NMT complementation plasmid.
(GBK)
Text S14 pCMHsNMT. Sequence and features of the human
NMT2 complementation plasmid.
(GBK)
Text S15 pCMLmNMT. Sequence and features of the
Leishmania major NMT complementation plasmid.
(GBK)
Text S16 pCMPvPGK. Sequence and features of the Plasmo-
dium vivax PGK complementation plasmid.
(GBK)
Text S17 pCMSmPGK. Sequence and features of the
Schistosoma mansoni PGK complementation plasmid.
(GBK)
Text S18 pCMTbPGK. Sequence and features of the Trypano-
soma brucei PGK complementation plasmid.
(GBK)
Text S19 pCMTcPGK. Sequence and features of the Trypano-
soma cruzi PGK complementation plasmid.
(GBK)
Text S20 pCMHsPGK. Sequence and features of the human
PGK complementation plasmid.
(GBK)
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Text S21 pCMLmPGKB. Sequence and features of the
Leishmania major PGKB complementation plasmid.
(GBK)
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